Ra Pharmaceuticals, Inc. Common Stock
RARX
RARX was delisted on the 1st of April, 2020.
64 hedge funds and large institutions have $230M invested in Ra Pharmaceuticals, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 7 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
2% less funds holding
Funds holding: 65 → 64 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
18% less capital invested
Capital invested by funds: $281M → $230M (-$50.7M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.56M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.83M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.84M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$2.27M |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$1.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$4.57M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$2.48M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$1.96M |
| 4 |
NC
Nexthera Capital
New York
|
-$1.91M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$986K |
RARX Hedge Fund Activity: Q3 2017 in Review
64 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q3 2017, worth a combined $230M — down 18% from $281M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of RARX and 6 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 26 added.
The largest buyer was Millennium Management, adding an estimated $6.56M. The largest seller was Acuta Capital Partners, cutting an estimated $4.57M.
- 64 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q3 2017, down from 65 in Q2 2017.
- Funds reported $230M of Ra Pharmaceuticals, Inc. Common Stock stock for Q3 2017, down 18% quarter-over-quarter.
- 6 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q3 2017 and 7 closed out, a net change of -1 holder.
- The largest Ra Pharmaceuticals, Inc. Common Stock buyer in Q3 2017 was Millennium Management, an estimated $6.56M added.
- The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q3 2017 was Acuta Capital Partners, an estimated $4.57M sold.
Based on aggregated 13F filings for Q3 2017.